Latest News: The ESMO-ESGO-ESP Consensus is advocating for the use of genomic instability tests validated in phase III trials Learn more
You can view the latest news, articles and announcements on EndoPredict below or visit our official Myriad Genetics press release page.
Two prospective real-world studies presented at SABCS show EndoPredict accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th December...
Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con...
New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ...
Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and ...